课题基金 / 基金详情

项目摘要

项目成果

ELIZABETH MARY SWISHER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Abstract The lack of an identifiable precursor lesion for ovarian carcinoma hinders attempts to design rational surveillance and chemoprevention for this deadly disease. Indeed, it is uncertain which are the specific cells in the female genital tract that transform into ovarian and primary peritoneal malignancies. A better understanding of the early steps in ovarian tumorigenesis would facillitate the development of new screening and prevention stratgies. Inherited mutations in the BRCA1 gene results in an approximate 40% lifetime risk of ovarian, tubal or peritoneal carcinoma. Current clinical recommendations for women with BRCA1 mutations include risk- reducing salpingo-oophorectomy (RRSO) by age 40 after completion of child-bearing. Our group and others have identified a high rate of high grade serous neoplasia in the fallopian tubes of BRCA1 mutation carriers undergoing RRSO. The frequency of occult tubal neoplasia exceeds that of ovarian neoplasia when using a detailed surgical and pathological protocol. We hypothesize that most ovarian and peritoneal carcinomas arising in BRCA1 mutation carriers are seeded from neoplastic cells arising in the fallopian tubes. This phenomenon could have important implications for the development of sporadic as well as hereditary ovarian carcinoma. The overall goal of the current proposal is to define a premalignant tubal phenotype in women with inherited BRCA1 mutations. The specific aims of this proposal are: 1. Characterize tubal epithelium in unaffected women with BRCA1 mutations and in women with BRCA1- associated or sporadic ovarian and peritoneal carcinomas. 2. Identify and characterize a gene expression signature associated with premalignant alterations in pathologically normal tubal epithelium from women with BRCA1 mutations. 3. Evaluate priority genes from Specific Aim 2 in inherited and sporadic ovarian and peritoneal carcinomas.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian cancer
  • 批准号:
    10661251
  • 项目类别:
  • 资助金额:
    $64.9万
  • 财政年份:
    2023
  • 负责人:
    ELIZABETH MARY SWISHER
  • 依托单位:
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy
  • 批准号:
    10028143
  • 项目类别:
  • 资助金额:
    $45.95万
  • 财政年份:
    2020
  • 负责人:
    ELIZABETH MARY SWISHER
  • 依托单位:
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy
  • 批准号:
    10405502
  • 项目类别:
  • 资助金额:
    $45.5万
  • 财政年份:
    2020
  • 负责人:
    ELIZABETH MARY SWISHER
  • 依托单位:
Methylation and Mutation Assay to Personalize PARP Inhibitor Therapy
  • 批准号:
    10200719
  • 项目类别:
  • 资助金额:
    $44.57万
  • 财政年份:
    2020
  • 负责人:
    ELIZABETH MARY SWISHER
  • 依托单位:
海外基金